CClinicalTrials.gg
CompletedNCT04714398Updated Sep 19, 2022

SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management

An interventional study of Opt-In Recruitment and Opt-Out Recruitment in Hypertension, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-19.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
425
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A 3-arm randomized pilot trial aimed at comparing the effectiveness of different approaches to recruiting patients to participate in a 6-month remote monitoring program for the management of hypertension (HTN).

Read the detailed description

The investigators will utilize the Way to Health (WTH) platform to develop and evaluate a new remote monitoring enrollment model that is integrated with routine clinical care at Penn Family Care (PFC), an academic family medicine practice in West Philadelphia. Among patients with poorly controlled HTN the investigators will:

  1. Compare the effect of sending eligible patients a blood pressure cuff with the mailed invitation letter and opt-out framing versus the more conventional method of phone calls following mailed letters.
  2. Evaluate the feasibility and effectiveness of a remote monitoring program with individualized stepped escalation for hypertension management.
02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • blood pressure
  • remote monitoring
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 425 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Between 18 and 75 years old with HTN (ICD-10 code I10)
  2. Has had at least one office visit at Penn Family Care (PFC) within the past 12 months (at time of chart review), with the last visit having a BP reading exceeding HTN guidelines (150/90 if >60 or, 140/90 if ages 21-59 yrs or has CKD or diabetes).
  3. Must have a cellular phone with texting capabilities
  4. Must be prescribed at least one medication for hypertension

Exclusion criteria

Exclusion Criteria:

  1. Has metastatic (Stage IV) cancer
  2. Has end stage renal disease
  3. Has congestive heart failure
  4. Has dementia
  5. BMI >= 50
  6. Is Non-English speaking requiring a translator
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
425 participants (actual)

Study arms

  • Experimental
    Opt-In Recruitment

    All recruitment messaging will be framed for patients as they must opt-in to participate in the remote monitoring program.

    Behavioral: Opt-In Recruitment

  • Experimental
    Opt-Out

    All recruitment messaging will be framed as though participation is the default, and patients must opt-out of participating in the remote monitoring program.

    Behavioral: Opt-Out Recruitment

  • No intervention
    Usual Care

    Patients in the usual care arm will not be contacted by study staff, they will not receive a blood pressure cuff, and they will not be asked to participate in any component of the blood pressure monitoring program.

Interventions

  • BehavioralOpt-In Recruitment

    Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.

  • BehavioralOpt-Out Recruitment

    Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.

06

What researchers measure

Primary outcomes

  1. Proportion Participating by Recruitment Method

    The proportion of patients participating in each study arm out of the number randomized to that study arm.

    Time frame: 6 months, from date of consent to end of remote monitoring program

Secondary outcomes

  1. Proportion Engaged by Recruitment Method

    The proportion of patients recruited by each method who are actively engaged with the program

    Time frame: 6 months, from date of consent to end of remote monitoring period

  2. Proportion with Controlled Blood Pressure by Monitoring vs. Usual Care

    The proportion with controlled blood pressure by remote monitoring and the proportion with controlled blood pressure by clinic visits (usual care).

    Time frame: 6 months, from date of consent to end of remote monitoring program

  3. Blood Pressure Trajectory by Recruitment Method

    The systolic and diastolic blood pressure trajectory by recruitment arm.

    Time frame: 6 months, from date of consent to end of remote monitoring program

  4. Proportion of BP Measurements Submitted by Recruitment Method

    The proportion of requested BP measurements submitted by each patient by recruitment arm

    Time frame: 6 months, from date of consent to end of remote monitoring program

07

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04714398
Lead sponsor
University of Pennsylvania
Responsible party
Shivan J Mehta (Principal Investigator, University of Pennsylvania) — Principal investigator
First posted
Jan 19, 2021
Start date
Feb 26, 2021
Primary completion
Mar 21, 2022
Completion
Aug 26, 2022
Last update
Sep 19, 2022

Study contacts

Shivan Mehta, MD, MBA
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion